Format

Send to

Choose Destination
Biol Pharm Bull. 2018;41(1):47-56. doi: 10.1248/bpb.b17-00521.

Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters.

Author information

1
Department of Medical Oncology and Translational Research, Graduate School of Pharmaceutical Sciences, Kumamoto University.
2
National Cancer Center Research Institute.
3
Chugai Pharmaceutical Co., Ltd.
4
Kitasato University Hospital.
5
Kumamoto University Hospital.
6
Saiseikai Kumamoto Hospital.
7
Kumamoto Central Hospital.
8
Kumamoto City Hospital.
9
Kumamoto Regional Medical Center.
10
Kumamoto Medical Center.
11
Shimane University Hospital.

Abstract

Determinants of interindividual variability in erlotinib pharmacokinetics (PK) and adverse events remain to be elucidated. This study with 50 Japanese non-small-cell lung cancer patients treated with oral erlotinib at a standard dose of 150 mg aimed to investigate whether genetic polymorphisms affect erlotinib PK and adverse events. Single nucleotide polymorphisms (SNPs) in genes encoding metabolizing enzymes (CYP1A1, CYP1A2, CYP2D6, CYP3A4, CYP3A5, UGT1A1, UGT2B7, GSTM1, and GSTT1) or efflux transporters (ABCB1, and ABCG2) were analyzed as covariates in a population PK model. The ABCB1 1236C>T (rs1128503) polymorphism, not ABCB1*2 haplotype (1236TT-2677TT-3455TT, rs1128503 TT-rs2032582 TT-rs1045642 TT), was a significant covariate for the apparent clearance (CL/F), with the TT genotype showing a 29.4% decrease in CL/F as compared with the CC and the CT genotypes. A marginally higher incidence of adverse events (mainly skin rash) was observed in the TT genotype group; however, patients with high plasma erlotinib exposure did not always experience skin rash. None of the other SNPs affected PK or adverse events. The ABCB1 genotype is a potential predictor for erlotinib adverse events. Erlotinib might be used with careful monitoring of adverse events in patients with ABCB1 polymorphic variants.

KEYWORDS:

adverse event; erlotinib; genetic polymorphism; population pharmacokinetics

PMID:
29311482
DOI:
10.1248/bpb.b17-00521
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for J-STAGE, Japan Science and Technology Information Aggregator, Electronic
Loading ...
Support Center